S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
OTCMKTS:ATBPF

Antibe Therapeutics Stock Forecast, Price & News

$0.31
+0.01 (+3.33 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.30
Now: $0.31▼
$0.31
50-Day Range
$0.24
MA: $0.28▼
$0.33
52-Week Range
$0.23
Now: $0.31▼
$0.64
Volume152,354 shs
Average Volume260,947 shs
Market Capitalization$119.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.37
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.46 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ATBPF
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.antibethera.com
Phone416-922-3460
Employees47

Debt

Debt-to-Equity RatioN/A
Current Ratio6.55
Quick Ratio5.95

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.51 million
Price / Sales15.97
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.01 per share
Price / Book30.99

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-14,540,000.00
Net Margins-273.96%
Return on Equity-176.23%
Return on Assets-106.91%

Miscellaneous

Outstanding Shares387,000,000
Market Cap$119.93 million
Next Earnings Date2/22/2021 (Estimated)
OptionableNot Optionable
$0.31
+0.01 (+3.33 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATBPF News and Ratings via Email

Sign-up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antibe Therapeutics (OTCMKTS:ATBPF) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Antibe Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Antibe Therapeutics.

What stocks does MarketBeat like better than Antibe Therapeutics?

Wall Street analysts have given Antibe Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Antibe Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Antibe Therapeutics.

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) announced its earnings results on Friday, November, 13th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $2.15 million for the quarter. Antibe Therapeutics had a negative net margin of 273.96% and a negative return on equity of 176.23%.
View Antibe Therapeutics' earnings history.

What price target have analysts set for ATBPF?

3 brokers have issued 12 month price targets for Antibe Therapeutics' shares. Their forecasts range from $1.40 to $1.50. On average, they expect Antibe Therapeutics' share price to reach $1.45 in the next year. This suggests a possible upside of 367.9% from the stock's current price.
View analysts' price targets for Antibe Therapeutics.

Are investors shorting Antibe Therapeutics?

Antibe Therapeutics saw a increase in short interest during the month of October. As of October 15th, there was short interest totaling 20,000 shares, an increase of 52.7% from the September 30th total of 13,100 shares. Based on an average daily volume of 125,000 shares, the days-to-cover ratio is presently 0.2 days.
View Antibe Therapeutics' Short Interest.

Who are some of Antibe Therapeutics' key competitors?

Some companies that are related to Antibe Therapeutics include AMAG Pharmaceuticals (AMAG), Akebia Therapeutics (AKBA), Merus (MRUS), RAPT Therapeutics (RAPT), BELLUS Health (BLUSF), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), Humanigen (HGEN), Humanigen (HGEN), Propanc Biopharma (PPCB), Wave Life Sciences (WVE), Marinus Pharmaceuticals (MRNS), Prothena (PRTA), resTORbio (TORC) and Molecular Templates (MTEM).
View all competitors.

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the following people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 62)
  • Dr. John Lawrence Wallace M.B.A., M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director (Age 63)
  • Mr. Alain Wilson M.B.A., MBA, Chief Financial Officer
  • Dr. David James Vaughan, Chief Devel. Officer (Age 70)
  • Mr. Scott Curtis C.F.A., M.Eng, CFA, Exec. VP
  • Ms. Christina Cameron B.B.A., VP of Investor Relations
  • Mr. Philip Stern, VP of Communications
  • Dr. Rami Batal M.B.A., Ph.D., Chief Commercial Officer
  • Ms. Ella Korets Smith M.B.A., M.Sc., Head of Regional Bus. Devel.
  • Dr. Joseph Stauffer, Chief Medical Officer (Age 54)

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPF."

How do I buy shares of Antibe Therapeutics?

Shares of ATBPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antibe Therapeutics' stock price today?

One share of ATBPF stock can currently be purchased for approximately $0.31.

How big of a company is Antibe Therapeutics?

Antibe Therapeutics has a market capitalization of $119.93 million and generates $7.51 million in revenue each year. Antibe Therapeutics employs 47 workers across the globe.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is www.antibethera.com.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The company can be reached via phone at 416-922-3460 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.